OverviewSuggest Edit

MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
TypePublic
Founded2012
HQSouth San Francisco, US
Websitemyokardia.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Dec 2019)235(+43%)
Job Openings25
Revenue (FY, 2019)$0(-100%)
Share Price (Nov 2020)$224.9
Cybersecurity ratingBMore

Key People/Management at MyoKardia

Tassos Gianakakos

Tassos Gianakakos

Chief Executive Officer, Director
William Fairey

William Fairey

Executive Vice President, Chief Commercial Officer
Jake Bauer

Jake Bauer

Chief Business Officer
Denelle Waynick

Denelle Waynick

Chief Legal Officer & Corporate Secretary
Taylor Harris

Taylor Harris

Chief Financial Officer
Ingrid Boyes

Ingrid Boyes

Chief Human Resources Officer
Show more

MyoKardia Office Locations

MyoKardia has offices in South San Francisco and Brisbane
South San Francisco, US (HQ)
333 Allerton Ave
Brisbane, US
1000 Sierra Point Pkwy
Show all (2)

MyoKardia Financials and Metrics

MyoKardia Revenue

USD

Net income (Q3, 2020)

(84.7m)

EBIT (Q3, 2020)

(85.4m)

Market capitalization (19-Nov-2020)

12.0b

Closing stock price (19-Nov-2020)

224.9

Cash (30-Sept-2020)

675.5m

EV

11.4b
MyoKardia's current market capitalization is $12 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

39.2m22.5m33.6m

Revenue growth, %

176%(43%)49%

General and administrative expense

16.3m22.0m38.4m61.7m

R&D expense

36.2m48.1m68.8m146.2m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.6m5.6m5.6m5.3m6.6m9.2m

General and administrative expense

5.5m5.1m5.9m7.3m8.9m11.0m13.6m13.9m17.7m19.9m20.3m26.3m

R&D expense

11.9m13.7m14.4m16.6m17.2m15.9m26.2m27.7m47.4m51.9m44.3m59.1m

Operating expense total

17.4m18.8m20.2m23.9m26.1m26.9m39.7m41.6m145.1m71.8m64.6m85.4m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

135.8m224.6m246.1m101.4m

Prepaid Expenses

1.4m1.9m4.8m7.7m

Current Assets

186.3m259.4m319.4m423.8m

PP&E

2.8m3.1m5.1m15.7m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(13.2m)(46.0m)(67.7m)(276.2m)

Depreciation and Amortization

1.1m1.3m1.6m1.9m

Accounts Payable

(434.0k)367.0k671.0k3.1m

Cash From Operating Activities

(20.9m)(9.8m)(64.8m)(241.8m)
USDFY, 2016

Revenue/Employee

502.6k

Financial Leverage

1.4 x
Show all financial metrics

MyoKardia Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018

Phase II Trials Products

1 1 2

Phase I Trials Products

2 2 2 1

Pre-Clinical Phase Products

1 3 3

Patents (US)

2 3 4 2
Show all operating metrics

MyoKardia Acquisitions / Subsidiaries

Company NameDateDeal Size
MyoKardia Australia Pty Ltd

MyoKardia Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

MyoKardia Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

MyoKardia Online and Social Media Presence

Embed Graph

MyoKardia Company Culture

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

MyoKardia News and Updates

MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten

EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation

MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020

ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients

MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy

Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacam…

MyoKardia Reports Third Quarter 2020 Financial Results

Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of MyoKardia, Inc. - MYOK

NEW YORK, Oct. 8, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating MyoKardia, Inc. ("MyoKardia" or the "Company") (MYOK) relating to...

SHAREHOLDER ALERT: WeissLaw LLP Investigates MyoKardia, Inc.

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MyoKardia, Inc. ("MYOK" or the "Company") (NASDAQ: MYOK) in connection with the proposed acquisition of the Company by...
Show more

MyoKardia Blogs

MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program

BRISBANE, Calif. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program , who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of

MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020

EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation BRISBANE, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the upcoming presentation of clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy  Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval Promising Portfolio of

MyoKardia Frequently Asked Questions

  • When was MyoKardia founded?

    MyoKardia was founded in 2012.

  • Who are MyoKardia key executives?

    MyoKardia's key executives are Tassos Gianakakos, William Fairey and Jake Bauer.

  • How many employees does MyoKardia have?

    MyoKardia has 235 employees.

  • Who are MyoKardia competitors?

    Competitors of MyoKardia include FORMA Therapeutics, Achaogen and AbbVie.

  • Where is MyoKardia headquarters?

    MyoKardia headquarters is located at 333 Allerton Ave, South San Francisco.

  • Where are MyoKardia offices?

    MyoKardia has offices in South San Francisco and Brisbane.

  • How many offices does MyoKardia have?

    MyoKardia has 2 offices.